x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

16:06

S1 Ep96: Combatting Stigmatization to Increase Lung...

Oncology On The Go ·

2024/02/12

In a conversation with CancerNetwork®, Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, spoke about factors that may contribute to feelings of stigmatization surrounding a lung cancer diagnosis, which may impact an individual’s decision to undergo screening for potential disease. Specifically, Carter-Bawa, director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation, detailed the stigmatization related to smoking and how public

en-us

11:25

S1 Ep95: Unraveling Resistance and Heterogeneity in...

Oncology On The Go ·

2024/02/05

Although strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure. CancerNetwork® spoke with leaders in the MCL field to better understand the aim of the consortium and

en-us

11:53

S1 Ep94: SIO/ASCO Guidelines for Integrative...

Oncology On The Go ·

2024/01/29

Integrative therapies have been proven to help reduce the adverse effects (AEs) of anxiety and depression in patients with cancer, according to Linda E. Carlson, PhD, RPsych. Carlson, Enbridge Research Chair in Psychosocial Oncology and a professor in the Department of Oncology, Cumming School of Medicine at the University of Calgary, explained how different therapies such as mindfulness-based interventions, yoga, and relaxation could work to manage anxiety and depression in patients with cancer

en-us

9:57

S1 Ep93: Jyoti S. Mayadev, MD, on Pembrolizumab/CRT...

Oncology On The Go ·

2024/01/22

In a conversation with CancerNetwork® prior to the FDA approval of pembrolizumab (Keytruda) plus chemoradiotherapy in FIGO stage III to IVA cervical cancer, Jyoti S. Mayadev, MD, spoke about how the regimen’s approval would be a “major step” for the aforementioned population and how she planned to integrate it into her care.1 Mayadev, a board-certified radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine,

en-us

22:10

S1 Ep92: Managing CDK4/6 Inhibitor, ADC Toxicity in...

Oncology On The Go ·

2024/01/15

In a conversation with CancerNetwork®, Sarah Donahue, MPH, NP, discussed strategies for managing adverse effects (AEs) associated with different drug classes for patients with metastatic breast cancer, ranging from antibody drug conjugates (ADCs) to CDK4/6 inhibitors. With respect to ADCs, Donahue, a nurse practitioner at University of California, San Francisco, and member of the Oncology Nursing Society, highlighted common AEs following treatment with trastuzumab deruxtecan (T-DXd; Enhertu) and

en-us

12:33

S1 Ep91: HER2CLIMB-02 Trial Shows ‘Interesting Data’...

Oncology On The Go ·

2024/01/09

In a recent conversation with CancerNetwork®, Sara A. Hurvitz, MD, FACP, senior vice president and director of the Clinical Research Division at Fred Hutch Cancer Center and head of the Division of Hematology and Oncology at the University of Washington Department of Medicine, discussed new treatment options for patients with metastatic HER2-positive breast cancer. In the discussion, Hurvitz highlighted findings from the phase 3 HER2CLIMB-02 trial (NCT03975647), which assessed the efficacy and

en-us

5:49

S1 Ep90: Frontline Chemo-Free Regimen Supported in...

Oncology On The Go ·

2024/01/01

In a conversation with CancerNetwork®, Amy Tiersten, MD, spoke about how findings from the phase 1/2 ASPIRE trial (NCT03304080) may support anastrozole (Arimidex) plus palbociclib (Ibrance), trastuzumab (Herceptin), and pertuzumab (Perjeta) as a first-line treatment for patients with hormone receptor (HR)–positive, HER2-positive metastatic breast cancer. Data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS)highlighted a clinical benefit rate of 97% (95% CI, 83%-100%; P

en-us

24:25

S1 Ep89: Expert Discusses Screening Advocacy, AI, and...

Oncology On The Go ·

2023/12/18

In a conversation with CancerNetwork®, Rakshanda Rahman, MD, FRCS, FACS, discussed a wide range of surgical therapy strategies and other developments in the breast cancer space, ranging from factors that should be considered for surgical decision-making to the evolution of artificial intelligence (AI) in the field. Rahman, a professor of Breast Surgical Oncology at Texas Tech University Health Sciences Center and the medical director of UMC Cancer Center, spoke about challenges associated with

en-us

9:03

S1 Ep88: Joleen Hubbard, MD, Highlights The “Exciting...

Oncology On The Go ·

2023/12/11

In a recent discussion with CancerNetwork®, Joleen Hubbard, MD, research collaborator with Mayo Clinic and deputy director for clinical research at Allina Health Cancer Institute in Minneapolis, Minnesota, discussed new opportunities for patients with colorectal cancer (CRC). In the discussion, Hubbard highlighted the potential of trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER2-expressing metastatic CRC based on studies including the phase 2 DESTINY-CRC01 trial (NCT03384940),

en-us

13:24

S1 Ep87: Adapting to a Robotic Workstation for...

Oncology On The Go ·

2023/12/04

CancerNetwork® spoke with Govindarajan Narayanan, MD about his practice becoming the first in the United States to successfully surgically treat a patient with a liver tumor using the Epione robot, as well as the process of transitioning from CT-based image guidance to the robotic workstation in his care.1 Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, both of

en-us

8:04

S1 Ep86: Tanios S. Bekaii-Saab, MD, Speaks to...

Oncology On The Go ·

2023/11/27

During an overview of the current standard of care for patients with colorectal cancer (CRC), Tanios S. Bekaii-Saab, MD noted that as molecular testing becomes more important, researchers are looking into how to best personalize therapy for optimal outcomes. He spoke with CancerNetwork® as part of an Around the Practice® program focused on testing and treatment options for patients with metastatic CRC. When discussing the future direction of CRC care strategies, it is possible that treatment

en-us

5:00

S1 Ep85: Multidisciplinary Care and New Treatment...

Oncology On The Go ·

2023/11/20

Kristen K. Ciombor, MD, MSCI, an assistant professor in the Division of Hematology/Oncology in the Department of Medicine at the Vanderbilt University Medical Center, recently spoke at an Around the Practice discussion regarding updates in the world of metastatic colorectal cancer (CRC). In this episode of the ONCOLOGY® On the Go Podcast, she discusses treatment updates, molecular testing options, and emerging targets in CRC. Ciombor also highlighted ongoing research in the space, including the

en-us

10:53

S1 Ep84: Multidisciplinary Care, Approval Updates,...

Oncology On The Go ·

2023/11/13

As part of an Around the Practice program, CancerNetwork® spoke with Misako Nagasaka, MD, PhD, about her current treatment strategies for patients with lung cancer as well as relevant updates and potential advancements in the non–small cell lung cancer (NSCLC) space. Nagasaka, a thoracic oncologist and associate clinical professor at the University of California, Irvine, discussed sequencing immunotherapy and chemotherapeutic agents depending on factors including EGFR and ALK mutations as well

en-us

11:19

S1 Ep83: Psychosocial Approach to Sexual Dysfunction...

Oncology On The Go ·

2023/11/08

Sexual dysfunction is a common problem for patients with and survivors of cancer that often remains undertreated. It can manifest in a variety of ways, including reduced libido, sexual pain, and vaginal dryness. Jennifer A. Vencill, PhD, LP, takes a biopsychosocial approach to sexual health, helping to address the psychological aspects of sexual dysfunction. In this episode of the ONCOLOGY On the Go Podcast, Vencill, a psychologist and sex therapist from the Mayo Clinic, spoke with CancerNetwork®

en-us

16:20

S1 Ep82: Experts Discuss Differences in Radiotherapy...

Oncology On The Go ·

2023/10/30

During Breast Cancer Awareness Month 2023, Rebecca M. Shulman, MD, an assistant professor in the Department of Radiation Oncology at Fox Chase Cancer Center, and Zachary Kiss, DO, a third-year resident physician in radiation oncology at Fox Chase, spoke about findings from their study, which assessed how BRCA1/2 mutations in patients with breast cancer do not appear to affect treatment outcomes with radiotherapy. Shulman and Kiss presented these findings as part of a poster session at the 2023

en-us

21:03

S1 Ep81: Pipeline Perspectives: Fruquintinib in...

Oncology On The Go ·

2023/10/02

In this episode of the ONCOLOGY On the Go Podcast, Arvind N. Dasari, MD, and Cathy Eng, MD, speak to data supporting fruquintinib (Elunate), a VEGFR-1, -2, and -3 inhibitor as a potential treatment for patients with metastatic colorectal cancer (CRC). Dasari is an associate professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. Eng is a David H. Johnson Chair in Surgical and

en-us

21:55

S1 Ep80: Navigating the Impact of Chemotherapy...

Oncology On The Go ·

2023/09/11

CancerNetwork® spoke with experts across multiple disciplines about the far-reaching impacts of the ongoing shortages of chemotherapy drugs including carboplatin and cisplatin, and how practices may be able to mitigate these challenges in the short and long term. Michael Ganio, PharmD, MS, BCPS, FASHP, described the causes of carboplatin and cisplatin being in short supply across the United States and how the FDA is working with Chinese manufacturers to import these chemotherapy agents. Ganio,

en-us

54:10

S1 Ep79: Frontline Forum: Testing and Targeted...

Oncology On The Go ·

2023/09/04

As part of a CancerNetwork® Frontline Forum program, Alexander I. Spira, MD, PhD, FACP; Millie Das, MD; Joshua K. Sabari, MD; and Misako Nagasaka, MD, PhD, reviewed updates in the management of EGFR exon 20 non–small cell lung cancer (NSCLC), and how these findings may apply to clinical practice. Spira, codirector of the Virginia Cancer Specialists Research Institute and director of the Thoracic and Phase I Program, and Das, a clinical associate professor of Medicine and Oncology at Stanford

en-us

49:29

S1 Ep78: Frontline Forum: Real-World Practice in...

Oncology On The Go ·

2023/08/14

As part of a CancerNetwork® Frontline Forum program, Joselle Cook, MBBS; Matthew James Pianko, MD; Luciano Costa, MD, PhD; and Timothy Schmidt, MD, reviewed key data updates and real-world practice findings in newly diagnosed multiple myeloma (NDMM), and how they may impact patient subgroups including those with transplant-ineligible NDMM. Cook, a hematologist specializing in the management of patients with multiple myeloma at the Mayo Clinic in Rochester, Minnesota; and Pianko, a hematologist

en-us

32:46

S1 Ep77: Relapsed/Refractory Multiple Myeloma Trial...

Oncology On The Go ·

2023/08/07

In a Twitter Spaces edition of the Oncology-On-The-Go podcast, Rafael Fonseca, MD and Krina Patel, MD, MSc spoke with CancerNetwork® about how key findings from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingmay impact the treatment paradigm. Fonseca, director of Innovation and Transformation Relationships at the Mayo Clinic in Phoenix, Arizona and Patel, an associate professor in the Department of Lymphoma/Myeloma in the Division of

en-us

222 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter